Two medicines call for high blood pressure

A blend of drugs is far better than just one 1 in treating hypertension, a UK research has suggested. etzashoha havalalazman netotmoto

The research in the Lancet concerned 1,200 individuals and observed commencing treatment with two drugs gave far better and quicker results, with fewer negative effects.

The method challenges standard medical practice where doctors give a patient 1 drug, then add an additional later if blood stress stays higher.

Virtually ten million individuals in the UK have hypertension.

Treatment with anti-hypertensive drugs is known to reduce the risk of stroke and heart disease.

A team led by researchers in the College of Cambridge, College of Glasgow and College of Dundee followed 1,254 patients with hypertension in ten nations.

They compared the effects of giving 1 drug (both aliskiren or amlodipine) or perhaps a blend of the two.

Patients given the blend of drugs had a 25% far better response during the initial six months compared with people on standard treatment, the research observed.

This equates to a six.5mm Hg increased reduction in systolic blood stress.

Participants had been also more unlikely to quit taking their medication on account of negative effects.

The two drugs may be given being a single pill, creating it less complicated for patients to take.

Professor Morris Brown of the College of Cambridge explained the research "breaks the mould for treating hypertension".

He explained: "Most patients can now be prescribed just one blend pill and understand that they are optimally safeguarded from strokes and heart attacks."

The British Heart Foundation, which can be funding follow-up investigation, explained very good control of blood stress is difficult to attain in many patients.

Associate medical director Professor Jeremy Pearson explained: "This research adds drastically to your evidence that commencing treatment for patients with hypertension with two medicines as opposed to 1 is secure, and much more effective than waiting to add the 2nd medicine later."

The investigation was funded by the pharmaceutical organization Novartis, which helps make amlodipine and aliskiren.

The blend pill was authorized by the FDA for use in the US very last year